These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 27037751)

  • 1. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
    Zahnow CA; Topper M; Stone M; Murray-Stewart T; Li H; Baylin SB; Casero RA
    Adv Cancer Res; 2016; 130():55-111. PubMed ID: 27037751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
    Zhang Y; Fatima N; Dufau ML
    Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review-Epigenetic therapy for cancer.
    Saleem M; Abbas K; Manan M; Ijaz H; Ahmed B; Ali M; Hanif M; Farooqi AA; Qadir MI
    Pak J Pharm Sci; 2015 May; 28(3):1023-32. PubMed ID: 26004710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of novel epigenetic molecular-targeting agents].
    Sowa Y; Sakai T
    Nihon Rinsho; 2015 Aug; 73(8):1263-7. PubMed ID: 26281676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation of gene expression as an anticancer drug target.
    Ferguson LR; Tatham AL; Lin Z; Denny WA
    Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
    Rondelet G; Wouters J
    Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
    Mai A; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines.
    Ou JN; Torrisani J; Unterberger A; Provençal N; Shikimi K; Karimi M; Ekström TJ; Szyf M
    Biochem Pharmacol; 2007 May; 73(9):1297-307. PubMed ID: 17276411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S; Herceg Z
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic mechanism of rRNA gene silencing: temporal order of NoRC-mediated histone modification, chromatin remodeling, and DNA methylation.
    Santoro R; Grummt I
    Mol Cell Biol; 2005 Apr; 25(7):2539-46. PubMed ID: 15767661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.
    Ganesan A; Nolan L; Crabb SJ; Packham G
    Curr Cancer Drug Targets; 2009 Dec; 9(8):963-81. PubMed ID: 20025605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylation directs DNA methylation in survivin gene silencing.
    Ma AN; Lu J; Zhou XJ; Wang YX
    Biochem Biophys Res Commun; 2011 Jan; 404(1):268-72. PubMed ID: 21130077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential role of epigenetic therapy in multiple myeloma.
    Smith EM; Boyd K; Davies FE
    Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.